Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma

医学 肝细胞癌 实体瘤疗效评价标准 放射外科 肝硬化 完全响应 放射科 核医学 放射治疗 临床试验 内科学 临床研究阶段 化疗
作者
Trevor R. P. Price,Susan M. Perkins,Kumaresan Sandrasegaran,M. Henderson,Mary A. Maluccio,Jennifer Zook,A. Joseph Tector,Rodrigo Vianna,Peter A.S. Johnstone,Higinia R. Cárdenes
出处
期刊:Cancer [Wiley]
卷期号:118 (12): 3191-3198 被引量:134
标识
DOI:10.1002/cncr.26404
摘要

Hepatocellular carcinoma (HCC) is increasing in incidence due to hepatitis C. Stereotactic body radiotherapy (SBRT) is a noninvasive, effective therapy in the management of liver malignancies. The authors evaluated radiological response in 26 patients with HCC treated with SBRT at Indiana University.Between March 2005 and June 2008, 26 patients with HCC who were not surgical candidates were enrolled in a phase 1 to 2 trial. Eligibility criteria included solitary tumors ≤ 6 cm or up to 3 lesions with sum diameters ≤ 6 cm, and well-compensated cirrhosis. All patients had imaging before, at 1 to 3 months, and every 3 to 6 months after SBRT.Patients received 3 to 5 fractions of SBRT. Median SBRT dose was 42 Gray (Gy) (range: 24-48 Gy). Median follow-up was 13 months. Per Response Evaluation Criteria in Solid Tumors (RECIST), 4 patients had a complete response (CR), 15 had a partial response (PR), and 7 achieved stable disease (SD) at 12 months. One patient with SD experienced progression marginal to the treated area. The overall best response rate (CR + PR) was 73%. In comparison, by European Association for the Study of the Liver (EASL) criteria, 18 of 26 patients had ≥ 50% nonenhancement at 12 months. Thirteen of 18 demonstrated 100% nonenhancement, being > 50% in 5 patients. Kaplan-Meier 1- and 2-year survival estimates were 77% and 60%, respectively.SBRT is effective therapy for patients with HCC with an overall best response rate (CR + PR) of 73%. Nonenhancement on imaging, a surrogate for ablation, may be a more useful indicator than size reduction in evaluating HCC response to SBRT in the first 6 to 12 months, supporting EASL criteria.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cestmoi发布了新的文献求助30
刚刚
量子星尘发布了新的文献求助10
刚刚
兰格格完成签到,获得积分10
刚刚
zhanghui完成签到 ,获得积分10
3秒前
一期一会完成签到,获得积分10
7秒前
Ran完成签到,获得积分20
8秒前
SciGPT应助yuzhi采纳,获得10
9秒前
田様应助咕咕采纳,获得10
11秒前
冷静凡天完成签到,获得积分10
14秒前
14秒前
14秒前
15秒前
爱吃汉堡的yyq完成签到,获得积分10
15秒前
16秒前
砍柴人完成签到,获得积分10
17秒前
17秒前
18秒前
19秒前
xiaozhao完成签到,获得积分10
19秒前
叁拾肆完成签到,获得积分10
20秒前
21秒前
LBX发布了新的文献求助20
21秒前
lxr发布了新的文献求助10
22秒前
22秒前
redking发布了新的文献求助30
22秒前
Ran关注了科研通微信公众号
23秒前
23秒前
白青发布了新的文献求助10
24秒前
24秒前
The one完成签到,获得积分10
24秒前
向绝山完成签到,获得积分10
25秒前
莲枳榴莲发布了新的文献求助10
25秒前
韩涵发布了新的文献求助10
26秒前
Ashley发布了新的文献求助10
28秒前
pengpur发布了新的文献求助10
28秒前
11111完成签到,获得积分10
28秒前
Chengcheng完成签到,获得积分10
29秒前
29秒前
29秒前
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975922
求助须知:如何正确求助?哪些是违规求助? 3520226
关于积分的说明 11201711
捐赠科研通 3256720
什么是DOI,文献DOI怎么找? 1798423
邀请新用户注册赠送积分活动 877576
科研通“疑难数据库(出版商)”最低求助积分说明 806452